Valsartan Cancer Health Risk: Persons Taking The Generic High Blood Pressure Medication Valsartan Should Be Aware of Several FDA Recalls on Tainted Valsartan Medications that May Cause Cancer by Texas Valsartan Cancer Lawyer Jason S. Coomer

The drug high blood pressure medication, Valsartan, has been under a recall worldwide because it was tainted with a known carcinogen, N-nitrosodimethylamine (NDMA). Persons who have been taking Valsartan since 2012 should be aware of the recall and consult their pharmacist, physician, and/or the FDA if they have any questions regarding the recall or if they think they have a tainted drug. Additional information regarding this recall is also listed below on this web page. Further, if you or a loved one has been taking Valsartan and have have been diagnosed with cancer, liver damage, or tumors, you should contact your health care provide to discuss the potential cause of your health issues as well as report the adverse action to the prescribing medical doctor and FDA as soon as possible.

For persons who have been diagnosed with cancer or families who have a loved one who was taking Valsartan and was diagnosed with cancer, please feel free to send an e-mail message to Texas Valsartan Cancer Lawyer Jason Coomer or use our online form for a free case evaluation.

Valsartan FDA Recall

Beginning in July 2018, the FDA began issuing a series of recalls on drug Valsartan. The initial recall was a voluntary recall by Major Pharmaceuticals because the Valsartan may contain the probable carcinogen Nnitrosodimethylamine (NDMA). This recall was for all lots which were supplied by Teva Pharmaceuticals and labeled as Major Pharmaceuticals. This initial recall was for Valsartan unit dose blisters with 100 tablets per carton and included lot numbers T01795, T01807, T01712, T01625, T01586, T01500, T01466, T01270, T01646, T01788, T01668, T01524, and T01269. Consumers with adverse reactions to these drugs were encouraged to report any adverse reactions or quality problems to the FDA.

The second recall was for Prinston Pharmaceutical Inc. dba Solco Healthcare LLC and included all lots of Valsartan Tablets, 40 mg, 80mg, 160mg, and 320mg; and Valsartan-Hydrochlorothiazide Tablets, 80mg/12.5mg, 160mg/12.5mg, 160mg/25mg, 320mg/12.5mg, and 320mg/25mg within expiry dates from Jul 2018 to Jan 2020.

The third recall was by Teva Pharmaceuticals for 29 lots of single and 51 lots of combination Valsartan medicines distributed under the Actavis label in the U.S.

The fourth voluntary recall was by Torrent Pharmaceuticals Limited which recalled 14 lots of Valsartan/Amlodipine/HCTZ tablets. Whereas the fifth voluntary recall was also by Torrent Pharmaceuticals Limited which voluntarily recalled ALL LOTS of Valsartan/Amlodipine/HCTZ, Valsartan/Amlodipine and Valsartan tablets within expiry Aug. 2018 to Jan 2020.

The sixth recall was by Mylan Pharmaceuticals and was a voluntary nationwide recall to the consumer level of select lots of Valsartan-containing products, including six lots of Amlodipine and Valsartan Tablets, USP (including the 5mg/160mg, 10mg/160mg, and 10mg/320mg strengths), seven lots of Valsartan Tablets, USP (including 40 mg, 80 mg, 160 mg, and 320 mg strengths), and two lots of Valsartan and Hydrochlorothiazide Tablets, USP 320mg/25mg strength. The batches were distributed between March 2017 and November 2018.

The seventh recall was by Teva Pharmaceuticals which initiated a voluntary recall in the United States of all lots of Amlodipine / Valsartan combination tablets and Amlodipine / Valsartan / Hydrochlorothiazide combination tablets

The eighth recall was by Mylan which initiated a voluntary recall on all lots of Valsartan-containing products within expiry. The 104 additional lots include 26 lots of Amlodipine and Valsartan Tablets, USP (including the 5mg/160mg, 10mg/160mg, 5mg/320mg and 10mg/320mg strengths), 51 lots of Valsartan Tablets, USP (including 40 mg, 80 mg, 160 mg and 320 mg strengths), and 27 lots of Valsartan and Hydrochlorothiazide Tablets, USP (80mg/12.5mg, 160mg/12.5mg, 160mg/25mg, 320mg/12.5mg and 320mg/25mg strengths). This lots were distributed from March 2017 to November 2018.

The ninth recall was by Aurobindo Pharma USA, Inc. which voluntary recalled of 80 lots of Amlodipine Valsartan Tablets USP, Valsartan HCTZ Tablets, USP and Valsartan Tablets USP. The expiry on these lots were from October 2019 to March 2021.

The tenth recall was in March 2019 by American Health Packaging which voluntarily recalled one lot of Valsartan Tablets, USP, 160 mg.

Additional recalls can be found on the FDA website.

Worldwide Recall of Valsartan is Related to The Drug Being Tainted With a Known Carcinogen

Valsartan has been recalled worldwide after it was found to contain N-nitrosodimethylamine (NDMA), a known carcinogen. The Valsartan contamination is thought to be from a Chinese manufacturing plant that may have used impure active pharmaceutical ingredients. This contamination may date back to 2012 and include lots not listed above. Further the contamination has potentially exposed many patients to Valsartan cancer risk, Valsartan liver damage, and Valsartan tumors.

The FDA recalls includes medicines from: Mylan Pharmaceuticals, Teva Pharmaceuticals, Aurobindo Pharma USA, Inc., Solco Healthcare, and Major Pharmaceuticals. Valsartan-containing products made by Teva Pharmaceuticals and Prinston Pharmaceuticals Inc. are labeled as A-S Medication Solutions LLC, AvKARE and RemedyRepack, according to the FDA. Two of these companies, A-S Medication and RemedyRepack, may also distribute Valsartan products not affected by the recall.

The following additional re-packagers are recalling or are expected to recall Valsartan-containing products:

• H. J. Harkins Company Inc. (this company was not originally included on either list)
• Lake Erie Medical, doing business as Quality Care Products LLC
• NuCare Pharmaceuticals Inc.
• Northwind Pharmaceuticals
• Proficient Rx
• Bryant Ranch Prepack Inc.

Valsartan is a High Blood Pressure Medication

The drug Valsartan is a prescription medication and is generic version of Diovan. It is commonly prescribed to treat high blood pressure and prevent heart failure. The FDA approved Valsartan as a treatment for high blood pressure, or hypertension, in adults and children age six and up. It’s also approved for use in adults to treat heart failure and to reduce the risk of death in patients who recently had a heart attack. Valsartan is in a class of hypertension medications known as angiotensin II receptor agonists that reduce the constriction of blood vessels so that blood flows more freely. Valsartan is a stand-alone medication or valsartan HCTZ, which combines valsartan with the diuretic hydrochlorothiazide.

Valsartan Cancer Lawyers, Texas Defective Drug Cancer Lawyers, and Texas Blood Pressure Medication Cancer Lawyers

Texas Dangerous Drug Attorney Jason Coomer commonly works with other lawyers throughout Texas, the United States, and the World including Houston Valsartan Cancer Lawyers, San Antonio Valsartan Cancer Lawyers, Dallas Valsartan Cancer Lawyers, New York Valsartan Cancer Lawyers, Chicago Valsartan Cancer Lawyers, and other Texas Cancer Death Lawyers. By sharing information and working together, his law firm and other firms throughout World are able to provide better representation for their clients.

If you have lost a loved one from cancer and have been using a Valsartan, please report the adverse action to the prescribing medical doctor as soon as possible. For more information on this topic, please feel free to contact Valsartan Cancer Lawyer and Blood Pressure Medication Cancer Lawyer Jason Coomer a Texas lawyer, or use our online submission form.

Januvia Pancreatic Cancer Death Lawyer, Janumet Pancreatic Cancer Lawyer, Sitagliptin Pancreatic Cancer Lawyer, Sitagliptin/Metformin Pancreatic Cancer Lawyer, Janumet Pancreas Cancer Lawyer, Sitagliptin Panreas Cancer Lawyer, and Januvia Pancreatitis Lawyer

If you have lost a loved one from Pancreatic Cancer or have suffered acute pancreatitis, hemorrhagic pancreatitis, accute necrotizing pancreatitis, or pancreas cancer; and have been using Januvia, please report the adverse action to the prescribing medical doctor as soon as possible. For more Januvia Pancreatic Cancer Lawsuit, Januvia Cancer Death Lawsuit, or Januvia Pancreas Cancer Lawsuit information, please feel free to contact Januvia Pancreatic Cancer Lawyer, Januvia Cancer Lawyer, and Januvia Pancreas Cancer Death Lawyer Jason Coomer a Texas lawyer, or use our online submission form.